Eledon Pharmaceuticals (ELDN) Share-based Compensation (2013 - 2026)

Eledon Pharmaceuticals' Share-based Compensation history runs 14 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Share-based Compensation fell 23.11% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.8 million (down 31.51% YoY) and the FY2025 annual result came in at $10.5 million, down 20.36% from the prior year.
• Share-based Compensation was $2.2 million for Q1 2026 at Eledon Pharmaceuticals, down from $2.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $6.6 million in Q4 2024 and bottomed at $1.4 million in Q1 2023.
• A 5-year average of $2.4 million and a median of $2.2 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation soared 284.91% — and 2025, when it tumbled 62.55%.
• Eledon Pharmaceuticals' Share-based Compensation stood at $1.5 million in 2022, then grew by 16.01% to $1.7 million in 2023, then surged by 284.91% to $6.6 million in 2024, then tumbled by 62.55% to $2.5 million in 2025, then declined by 10.67% to $2.2 million in 2026.
• Business Quant data shows ELDN's Share-based Compensation at $2.2 million in Q1 2026, $2.5 million in Q4 2025, and $2.4 million in Q3 2025.